Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dimercaptosuccinic acid
- Development stage
- Unknown
- Lead developer
- Sonoran University of Health Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dimercaptosuccinic acid (DMSA), also known as succimer, is an orally active small molecule chelating agent. It is FDA-approved for the treatment of lead poisoning in children, where it functions by binding to heavy metals to form water-soluble complexes that are subsequently excreted in the urine. The Southwest College of Naturopathic Medicine (SCNM) investigated DMSA as an off-label therapy for children with autism spectrum disorder (ASD) who exhibit evidence of significant heavy metal exposure (including lead, mercury, and antimony). The rationale for this application is based on the hypothesis that heavy metal toxicity and impaired detoxification pathways contribute to the pathophysiology of ASD. A Phase 1/2 clinical trial (NCT00811083) evaluated the safety and efficacy of multiple rounds of DMSA administration in reducing autistic symptoms by addressing underlying metal burdens.
- Brand names
- Chemet
- Other names
- succimer2,3-dimercaptosuccinic acidmeso-2,3-dimercaptosuccinic acid
Beyond the preview
Go deeper on dimercaptosuccinic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dimercaptosuccinic acid.